Dear Reader,
Every single day a new drug sits waiting for FDA approval can cost the company behind it approximately $500,000.
Miss by a month and the meter can run to $15 million. Miss by a quarter and it can reach $45 million.
Now you understand why this hidden AI company may have big pharma trapped in the best possible way for investors.
See why this $500,000-a-day problem has my full attention.
I am Alexander Green, Chief Investment Strategist of The Oxford Club for more than two decades. I bought Apple in 1996, and Amazon and Netflix below $3 split-adjusted.
Those wins taught me to look beyond the loudest hardware story and ask a more important question: Which company becomes so embedded in an industry that removing it feels reckless?
I believe I have found one.
Nineteen of the top 20 biopharma companies run regulatory operations through its platform. Their clinical data, submissions, and compliance records live inside the system.
Now comes the pressure point: customers are being moved from a legacy product to the company’s newer AI-powered platform. More than 125 customers are already live, and Clinical Data AI applications are scheduled to go live in December 2026.
When one lost day can carry a six-figure cost, switching to an unproven rival could be an executive-level gamble.
Discover why big pharma may be unable to walk away from this platform.
This is Phase 2 of the AI boom: not building chips, but using AI to take control of an essential, expensive workflow. The deeper the platform goes, the harder it may become to replace.
That December rollout gives investors a concrete reason to pay attention now, while the company is still hiding in plain sight.
The December rollout is on the calendar. The stock is still hiding in plain sight.
See the complete biopharma AI case before the December rollout.
Good investing,
Alexander Green
Chief Investment Strategist, The Oxford Club
P.S. One day of FDA delay can cost roughly $500,000. This platform already sits inside 19 of the top 20 biopharma giants, and its Clinical Data AI rollout is scheduled for December. See the stock behind the rollout here.
Ford and GM Are Buying Time. The Clock May Be Running Out.
Jim Farley said the quiet part out loud again Friday. At the 50th annual Automotive News Conference in Detroit, Ford’s CEO declared it is “too late” for Europe to regain the upper hand over the inexpensive, futuristic vehicles coming out of Asia. Then he went further. While sales in China have collapsed for Ford, GM, and Stellantis, it is not Chinese buyers that the U.S. giants have to worry about: it is the broader international landscape, including at home, even with present import bans in place. That framing lands differently when you look at what Q3 sales data actually showed.
The Bull Case: Hybrids Hold the Line, Tariffs Buy Time
Start with what is working. Excluding the planned phase-out of the Escape and Corsair, Ford estimates its third-quarter retail share increased approximately 0.4 percentage points year over year to 12.1%, with F-Series September sales rising 2.4%, keeping the truck on track for its 50th consecutive year as America’s best-selling pickup. The Maverick Hybrid set a third-quarter sales record at 27,793 trucks, up 59.6%. Ford is not a hybrid laggard: it is leaning into the powertrain that the market is actually buying.
Toyota’s quarter confirms the opportunity. Toyota Motor North America reported third-quarter U.S. sales of 633,223 vehicles, up 0.6%, with electrified vehicles accounting for 57.4% of total sales: 363,367 units, a 28.5% jump. Gas prices are elevated, with an AAA national average around $4.41 in early October, and shoppers are leaning toward hybrids. Detroit can play that hand too, provided it moves fast enough.
On the competitive threat itself, the walls are still up. A Commerce Department rule bars carmakers with a sufficient China link from selling connected vehicles in the U.S. from model year 2027, even if the cars are built domestically. On July 22, the Senate Commerce Committee unanimously approved and advanced the Connected Vehicle Security Act of 2026, to ban internet-connected vehicles and technology linked to foreign adversaries. For now, BYD and its peers remain locked out of the world’s most profitable auto market.
The Bear Case: The Demand Was the Subsidy
The Q3 EV numbers for GM are not easy to contextualize away. GM delivered 25,213 EVs in the U.S. during Q3 2026, compared with 66,501 units during the same period in 2025: a 62.1% decline. The steepest drop came from the Chevrolet Equinox EV, once GM’s best-selling electric vehicle, which collapsed 92.4% compared with Q3 2025. The bears argue the comparison itself is the story: EV sales fell about 62% from a year ago, when buyers rushed to claim the $7,500 federal tax credit before it expired at the end of September 2025. Strip out the subsidy, and the organic demand was a fraction of what the record books showed.
GM offers only one hybrid vehicle, a Corvette, leaving it without the broader electrified lineup that helped rivals post gains. That single fact is more damaging than any quarterly comparison. While Toyota and Hyundai converted high gas prices into record hybrid share, GM had no product positioned to capture it. As a result, Toyota narrowed GM’s year-to-date lead in U.S. sales to about 136,000 vehicles through the end of Q3.
Globally, the pressure is not standing still. In the first half of 2026, BYD’s overseas sales grew 70.7% to 792,256 units. Chinese brands already hold roughly one-tenth of Europe’s car market, depending on how you count Chinese ownership and legacy European brands. Farley himself says it is “too late” for Europe to block them. The parallel to the U.S. is not lost on anyone paying attention.
Where the Evidence Leads
The bull case is real but time-sensitive. Ford’s truck franchise and hybrid momentum give it a defensible near-term position. The tariff wall and connected-vehicle rules provide a regulatory moat that does not exist in Europe. Those advantages are worth something.
But the bear case is structurally sharper. GM entered the post-subsidy era with almost no hybrid exposure and an EV lineup whose sales were largely pulled forward by a government check. Behind Europe’s tariff wall, Chinese EVs still sell for 21% less on average, according to Transport and Environment. If that pricing gap persists, a tariff is a delay, not a solution. Farley himself acknowledged as much at the conference: he emphasized that European efforts to counter Chinese automakers are “too late,” and added, “We can’t expect to keep them out forever.”
Watch two things from here: GM’s hybrid product roadmap and whether Congress passes a permanent ban before year-end. Congress is weighing a permanent ban, and automakers want it passed by the end of December, Reuters reported. If neither materializes on schedule, the bull case gets considerably harder to hold.
